Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction

Company Overview - Apogee Therapeutics is a biotechnology company focused on developing extended half-life monoclonal antibodies for treating atopic dermatitis and chronic obstructive pulmonary disease (COPD) [6][7] - The company aims to address significant unmet needs in the healthcare market, particularly in dermatology and respiratory diseases [6][7] - As of February 17, 2026, the company's market capitalization is $3.82 billion, with a share price of $69.64, reflecting a one-year price change of 99.37% [4][6] Recent Developments - On February 17, 2026, Perceptive Advisors disclosed the purchase of 978,662 shares of Apogee Therapeutics, valued at approximately $61.64 million [1][2] - Following this transaction, Perceptive Advisors holds a total of 2,330,651 shares, with the value of their position increasing by $122.20 million due to new purchases and share price appreciation [2] - This acquisition represents 3.14% of Perceptive Advisors' 13F assets under management (AUM) as of December 31, 2025 [6] Financial Performance - Apogee Therapeutics reported a net income of -$253.67 million over the trailing twelve months (TTM) [4] - The company is expected to generate revenue from product sales upon regulatory approval of its therapies [7] - Long-term investors are encouraged to focus on the differentiation of the pipeline in atopic dermatitis and COPD, as well as the company's capital discipline [12]